Literature DB >> 1398935

Similarity between the group B and A streptococcal C5a peptidase genes.

P P Cleary1, J Handley, A N Suvorov, A Podbielski, P Ferrieri.   

Abstract

Group B streptococci (GBS) and group A streptococci (GAS) are known to have surface-associated peptidase activity which specifically cleaves C5a (C5a-ase), the primary chemotaxin for polymorphonuclear leukocytes. Amplification products were obtained from GBS genomic DNA template by using the polymerase chain reaction and primers corresponding to the C5a peptidase gene of GAS (scpA12). A restriction map of the GBS full-length amplified gene (scpB) was developed. The scpB restriction map was found to be highly similar to that of the analogous gene in GAS. A 50-bp deletion was located near the 5' end of scpB in a region where repeat sequences are found in scpA12. Hybridization experiments confirmed that other serotypes of GBS also carry an scpB-like gene. These results show that GBS contain a gene, scpB, which is very similar to that harbored by M12 GAS. The probability that scpB encodes the C5a-ase protein is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398935      PMCID: PMC257458          DOI: 10.1128/iai.60.10.4239-4244.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

Review 1.  Recent advances in the polymerase chain reaction.

Authors:  H A Erlich; D Gelfand; J J Sninsky
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

2.  Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci.

Authors:  P P Cleary; J Peterson; C Chen; C Nelson
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  A simple method for the isolation of chromosomal DNA from gram positive or acid-fast bacteria.

Authors:  C Bollet; M J Gevaudan; X de Lamballerie; C Zandotti; P de Micco
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

Review 4.  Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases.

Authors:  R J Siezen; W M de Vos; J A Leunissen; B W Dijkstra
Journal:  Protein Eng       Date:  1991-10

5.  Purification of the proteinase from group B streptococci that inactivates human C5a.

Authors:  J F Bohnsack; X N Zhou; P A Williams; P P Cleary; C J Parker; H R Hill
Journal:  Biochim Biophys Acta       Date:  1991-08-30

6.  Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.

Authors:  J F Bohnsack; K W Mollison; A M Buko; J C Ashworth; H R Hill
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

7.  Purification and characteristics of the streptococcal chemotactic factor inactivator.

Authors:  D E Wexler; P P Cleary
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes.

Authors:  C C Chen; P P Cleary
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

9.  Application of the polymerase chain reaction to study the M protein(-like) gene family in beta-hemolytic streptococci.

Authors:  A Podbielski; B Melzer; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

10.  A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen.

Authors:  G J Russell-Jones; E C Gotschlich; M S Blake
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  21 in total

1.  Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes.

Authors:  Irina V Koroleva; Androulla Efstratiou; Alexander N Suvorov
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

2.  Conservation of the C5a peptidase genes in group A and B streptococci.

Authors:  I Chmouryguina; A Suvorov; P Ferrieri; P P Cleary
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 3.  Common themes in microbial pathogenicity revisited.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

4.  Clinical strains of Streptococcus agalactiae carry two different variants of pathogenicity island XII.

Authors:  Eugenia Kuleshevich; Joseph Ferretti; Ilda Santos Sanches; Natesan Balasubramanian; Barbara Spellerberg; Androulla Efstratiou; Paula Kriz; Kornelia Grabovskaya; Olga Arjanova; Alevtina Savitcheva; Valentin Shevchenko; Anton Rysev; Alexander Suvorov
Journal:  Folia Microbiol (Praha)       Date:  2017-03-18       Impact factor: 2.099

5.  Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus.

Authors:  Y Ji; B Carlson; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease.

Authors:  M Hauge; C Jespersgaard; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Analysis of RogB-controlled virulence mechanisms and gene repression in Streptococcus agalactiae.

Authors:  Heike Gutekunst; Bernhard J Eikmanns; Dieter J Reinscheid
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Emergence and global dissemination of host-specific Streptococcus agalactiae clones.

Authors:  Uffe B Skov Sørensen; Knud Poulsen; Claudia Ghezzo; Immaculada Margarit; Mogens Kilian
Journal:  MBio       Date:  2010-08-24       Impact factor: 7.867

9.  Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.

Authors:  A Podbielski; O Blankenstein; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

10.  C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.

Authors:  Y Ji; L McLandsborough; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.